A5077188817- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Breast Lesions and Carcinomas
- Cancer Cells and Metastasis
- Radiomics and Machine Learning in Medical Imaging
- HER2/EGFR in Cancer Research
- Esophageal Cancer Research and Treatment
- Cancer Research and Treatments
- Immunotherapy and Immune Responses
- Advanced Breast Cancer Therapies
- Epigenetics and DNA Methylation
- Gastric Cancer Management and Outcomes
- Cancer Treatment and Pharmacology
- Infectious Disease Case Reports and Treatments
- Pancreatic and Hepatic Oncology Research
- Abdominal vascular conditions and treatments
- Autoimmune Neurological Disorders and Treatments
- BRCA gene mutations in cancer
- Gastrointestinal Tumor Research and Treatment
- Gastrointestinal disorders and treatments
- Nonmelanoma Skin Cancer Studies
- Tattoo and Body Piercing Complications
- Lung Cancer Research Studies
- Genetics and Neurodevelopmental Disorders
MedStar Georgetown University Hospital
2014-2024
Georgetown University
2014-2024
Georgetown University Medical Center
2018-2023
Inova Health System
2019
National Cancer Institute
2019
Moffitt Cancer Center
2019
Quantum Leap Healthcare Collaborative
2019
Mayo Clinic
2018
University of Alabama at Birmingham
2018
Mayo Clinic in Arizona
2018
<h3>Importance</h3> Pathologic complete response (pCR) is a known prognostic biomarker for long-term outcomes. The I-SPY2 trial evaluated if the strength of this clinical association persists in context phase 2 neoadjuvant platform trial. <h3>Objective</h3> To evaluate pCR with event-free survival (EFS) and distant recurrence–free (DRFS) subpopulations women high-risk operable breast cancer treated standard therapy or one several novel agents. <h3>Design, Setting, Participants</h3>...
<h3>Importance</h3> Residual cancer burden (RCB) distributions may improve the interpretation of efficacy in neoadjuvant breast trials. <h3>Objective</h3> To compare RCB between randomized control and investigational treatments within subtypes explore relationship with survival. <h3>Design, Setting, Participants</h3> The I-SPY2 is a multicenter, platform adaptive, clinical trial US that compares, by subtype, agents combination chemotherapy vs alone adult women stage 2/3 at high risk early...
Abstract Chemotherapy and immune checkpoint inhibitors have a role in the post-neoadjuvant setting patients with triple-negative breast cancer (TNBC). However, effects of nivolumab, inhibitor, capecitabine, or combination changing peripheral immunoscore (PIS) remains unclear. This open-label randomized phase II OXEL study (NCT03487666) aimed to assess immunologic terms change PIS (primary endpoint). Secondary endpoints included presence ctDNA, toxicity, clinical outcomes at 2-years...
We report a 62-year-old white woman with metastatic choroidal melanoma who developed immune checkpoint inhibitor (ICI)-induced enteritis and grade 3 diarrhea refractory to steroids infliximab. Her quickly resolved after infusion of vedolizumab, the patient was able taper down steroids. Vedolizumab's mechanism action its gut specificity have potential reverse immune-induced enterocolitis without neutralizing or reversing therapeutic benefit ICI on malignancy.
Balancing the potential for durable remissions with autoimmune-like toxicities is a key clinical challenge in use of immune checkpoint inhibitors (ICI). Certain are associated an increased response rate; however, molecular underpinnings this association poorly understood. Here, we report patient wide spread uveal melanoma who had exceptional to treatment ipilimumab and nivolumab, but suffered severe immune-related sequelae, including central serous retinopathy retinal detachment, tinnitus,...
Circulating tumor cells (CTCs), a population of cancer that represent the seeds metastatic nodules, are promising model system for studying metastasis. However, expansion patient-derived CTCs ex vivo is challenging and dependent on collection high numbers CTCs, which ultra-rare. Here we report development combined CTC cultured CTC-derived xenograft (CDX) platform expanding from colon, lung, pancreatic cancers. The propagated yielded highly aggressive could be used to routinely robustly...
Pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC) in breast cancer strongly correlates with overall survival and has become the standard end point trials. However, there is controversy regarding whether definition of pCR should exclude or permit presence residual ductal carcinoma situ (DCIS).To examine association DCIS surgical specimens for points to inform standards assessment pathologic response.The study team analyzed NAC 3-year event-free (EFS), distant...
Abstract Background: Pathological complete response (pCR) is accepted by FDA as a surrogate endpoint for accelerated approval of targeted agents in combination with chemotherapy based on better long-term outcomes compared to residual disease (Cortazar 2014). Methods: The multi-center, adaptively-randomized I-SPY2 platform trial uses pCR the primary identify investigational that will improve women stage 2/3 breast cancer high risk early recurrence, across all signatures, hormone receptor...
Abstract Liver cancer is associated with genetic mutations caused by environmental exposures, including occupational exposure to alpha radiation emitted plutonium. We used whole exome sequencing (WES) characterize somatic in 3 histologically distinct primary liver tumors (angiosarcoma of the (ASL), cholangiocarcinoma (CCA) and hepatocellular carcinoma (HCC)) from Mayak worker subjects occupationally exposed ionizing (IR) investigate contribution IR mutational landscape cancer. DNA sequence...
Enteric duplication cysts (EDCs) are benign congenital anomalies that found incidentally in adults. Gastric (GDCs) the least common subtype of EDC, but when located near pancreas, may resemble other neoplastic conditions. We report a case GDC adjacent to pancreas with high cystic fluid amylase and carcinoembryonic antigen (CEA) 3 different epithelia (respiratory, gastric, intestinal), all diagnosed via endoscopic ultrasound fine-needle aspiration.
Abstract Chemotherapy and immune checkpoint inhibitors have a role in the post-neoadjuvant setting patients with triple-negative breast cancer (TNBC). However, effects of nivolumab, inhibitor, capecitabine, or combination changing peripheral immunoscore (PIS) remains unclear. This open-label randomized phase II OXEL study ( NCT03487666 ) aimed to assess immunologic terms change PIS (primary endpoint). Secondary endpoints include presence ctDNA, toxicity, clinical outcomes at 2-years...
Paraneoplastic neurologic disorder may be the initial manifestation of a tumor, with diagnosis malignancy commonlyfound within six months onset symptoms. This is usually made on clinical grounds, as antineuronalantibodies are infrequently positive, though anti-Hu antibodies have been associated commonly lung cancer. Typically,neurologic manifestations germinomas include limbic and brainstem encephalitis in association anti-Ma2 antibodies.To our knowledge, not paraneoplastic cerebellar...
TPS9152 Background: Checkpoint inhibitor immunotherapy (CPI) offers durable, immune-mediated, anti-tumor responses to a subset of patients (pts) with advanced non-small cell lung cancer (NSCLC), but not all derive meaningful benefit. Two clinical unmet needs where CPI has fallen short include EGFR-mutated NSCLC, is minimally effective, and NSCLC intrinsic or acquired resistance currently available CPI. Novel combination strategies have shown promise. agents that demonstrated synergy the...
Abstract Background: Patients achieving a pathologic complete response (pCR) following neoadjuvant therapy have significantly improved event-free survival relative to those who do not; and pCR is an FDA-accepted endpoint support accelerated approval of novel agents/combinations in the treatment high risk early stage breast cancer. Previous studies shown that recurrence increased with increasing burden residual disease (as assessed by RCB index). As well, these suggest patients minimum (RCB-I...